Nasdaq

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN ...

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date ...
Seeking Alpha

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that ...
Nasdaq

X4 Pharmaceuticals Reports Progress in Phase 3 Chronic Neutropenia Trial and Financial Results for Q1 2025

X4 Pharmaceuticals has progressed significantly in its ongoing Phase 3 clinical trial, known as the 4WARD trial, targeting chronic neutropenia, aiming for full enrollment by the end of 2025 and ...
Seeking Alpha

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (XFOR) (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the ...
Monthly Prescribing Reference

FDA Eliminates Clozapine REMS Program Requirement

The FDA still recommends prescribers monitor patients’ ANC levels according to the prescribing information. The Food and Drug Administration (FDA) has removed the risk evaluation and mitigation ...
Medscape

Late-onset Neutropenia Following Rituximab Therapy

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...